Lifevantage (LFVN) Competitors $13.59 -0.13 (-0.95%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$13.57 -0.02 (-0.15%) As of 07/7/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. STOK, SANA, MRVI, URGN, AUTL, CDXC, CDTX, ABUS, EOLS, and UPBShould you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), Evolus (EOLS), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Lifevantage vs. Its Competitors Stoke Therapeutics Sana Biotechnology Maravai LifeSciences Urogen Pharma Autolus Therapeutics ChromaDex Cidara Therapeutics Arbutus Biopharma Evolus Upstream Bio Stoke Therapeutics (NASDAQ:STOK) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do insiders & institutionals believe in STOK or LFVN? 35.3% of Lifevantage shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 20.7% of Lifevantage shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer STOK or LFVN? In the previous week, Stoke Therapeutics had 11 more articles in the media than Lifevantage. MarketBeat recorded 14 mentions for Stoke Therapeutics and 3 mentions for Lifevantage. Lifevantage's average media sentiment score of 0.88 beat Stoke Therapeutics' score of 0.18 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Lifevantage 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, STOK or LFVN? Lifevantage has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M17.46-$88.98M$0.7914.80Lifevantage$200.16M0.85$2.94M$0.6919.70 Do analysts recommend STOK or LFVN? Stoke Therapeutics currently has a consensus price target of $23.20, indicating a potential upside of 98.46%. Lifevantage has a consensus price target of $30.50, indicating a potential upside of 124.43%. Given Lifevantage's higher probable upside, analysts clearly believe Lifevantage is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, STOK or LFVN? Stoke Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Lifevantage has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Is STOK or LFVN more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Lifevantage's net margin of 4.12%. Lifevantage's return on equity of 34.67% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.33% 19.08% 15.72% Lifevantage 4.12%34.67%15.24% SummaryStoke Therapeutics beats Lifevantage on 9 of the 17 factors compared between the two stocks. Get Lifevantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.71M$16.68B$5.52B$9.02BDividend Yield1.31%1.40%5.24%4.08%P/E Ratio19.7018.6627.1920.04Price / Sales0.852.29413.81108.84Price / Cash15.5617.9926.2128.59Price / Book6.633.807.925.55Net Income$2.94M$430.42M$3.17B$248.49M7 Day Performance1.49%-0.50%1.78%4.87%1 Month Performance8.55%-0.29%1.26%6.63%1 Year Performance146.64%22.77%33.30%20.38% Lifevantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifevantage4.2803 of 5 stars$13.59-0.9%$30.50+124.4%+128.4%$172.71M$200.16M19.70260News CoverageSTOKStoke Therapeutics3.9941 of 5 stars$11.35-2.4%$23.20+104.4%-10.9%$634.96M$36.56M14.37100SANASana Biotechnology2.5575 of 5 stars$2.73-2.8%$8.60+215.0%-39.1%$633.59MN/A-3.10380MRVIMaravai LifeSciences3.8588 of 5 stars$2.41-2.4%$6.64+175.5%-62.8%$629.01M$259.18M-2.11610Positive NewsURGNUrogen Pharma4.4473 of 5 stars$13.70+1.6%$32.86+139.8%-15.1%$621.99M$90.40M-4.31200Analyst ForecastAUTLAutolus Therapeutics2.1161 of 5 stars$2.28-1.3%$9.32+308.8%-34.5%$614.79M$10.12M-2.59330CDXCChromaDex3.1826 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120CDTXCidara Therapeutics4.2161 of 5 stars$48.71-1.5%$57.14+17.3%+300.8%$603.74M$1.27M-1.6590High Trading VolumeABUSArbutus Biopharma1.4257 of 5 stars$3.09-1.3%$5.50+78.0%+0.6%$599.48M$6.17M-7.5490EOLSEvolus3.6664 of 5 stars$9.21+0.8%$23.75+157.9%-16.4%$589.31M$266.27M-10.35170Positive NewsUPBUpstream BioN/A$10.98+0.5%$56.50+414.6%N/A$587.97M$2.37M0.0038 Related Companies and Tools Related Companies Stoke Therapeutics Competitors Sana Biotechnology Competitors Maravai LifeSciences Competitors Urogen Pharma Competitors Autolus Therapeutics Competitors ChromaDex Competitors Cidara Therapeutics Competitors Arbutus Biopharma Competitors Evolus Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifevantage Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifevantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
